Generic Name: ripretinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Deciphera

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Qinlock is a kinase inhibitor approved for people with previously treated advanced gastrointestinal stromal tumor (GIST).

General Info

Qinlock is a tyrosine kinase inhibitor that targets KIT and PDGFRA mutations that drive cancer cell growth. It was approved for people who have already used at least three other kinase inhibitors, including Gleevec (imatinib).

The Phase III INVICTUS trial showed that people treated with Qinlock had a higher response rate and longer progression-free survival than with those who received a placebo. Qinlock was first approved in May 2020.


Dosing Info:

Qinlock is a tablet taken once daily with or without food.

Side Effects

Common adverse reactions include hair loss, fatigue, nausea, vomiting, abdominal pain, constipation, diarrhea, decreased appetite, muscle pain and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious adverse events may include new skin malignancies, severe hypertension, heart problems and slow wound healing. Qinlock can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: May 21, 2020